Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.0 - $31.23 $0 - $41.4 Million
-1,325,000 Closed
0 $0
Q4 2023

May 15, 2024

BUY
$12.46 - $29.95 $16.5 Million - $39.7 Million
1,325,000 New
1,325,000 $39.3 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Taconic Capital Advisors LP Portfolio

Follow Taconic Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Taconic Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Taconic Capital Advisors LP with notifications on news.